Next-generation genomics can be described as the combination of sequencing technologies and big data analytics. The potential impact of this disruptive technology in health care will be primarily realized through extending and enhancing lives through faster disease detection, more precise diagnoses, new drugs, and more tailored disease treatments. The technical challenges inherent in genetic engineering technology are great but may be less formidable than the social, ethical, and regulatory concerns it may generate.
SPEAKERS
Timothy Behrens, Senior Director, Human Genetics, Genentech
Francis deSouza, President, Illumina Corporation
Robert L. Nussbaum, Chief, Department of Medicine & UCSF Institute for Human Genetics, UCSF
MODERATOR:
Michael Chui, Partner, McKinsey Global Institute